{"name":"MERCK SHARP DOHME","slug":"merck-sharp-dohme","ticker":"","exchange":"","domain":"mercksharpdohme.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1443000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Winrevair","genericName":"SOTATERCEPT","slug":"sotatercept","revenue":1443000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2025-01-01","label":"Winrevair first approved","drug":"Winrevair","drugSlug":"sotatercept","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-07","label":"WINREVAIR Phase 3 readout (Pulmonary Arterial Hypertension)","drug":"WINREVAIR","drugSlug":"sotatercept-csrk","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":1443000000,"percentOfTotal":100,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Winrevair","genericName":"SOTATERCEPT","slug":"sotatercept","indication":"pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension)","status":"marketed","revenue":1443000000},{"name":"WINREVAIR","genericName":"SOTATERCEPT-CSRK","slug":"sotatercept-csrk","indication":"Pulmonary Arterial Hypertension","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"KEYTRUDA QLEX","genericName":"BERAHYALURONIDASE ALFA-PMPH","slug":"berahyaluronidase-alfa-pmph","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Winrevair","genericName":"SOTATERCEPT","slug":"sotatercept","phase":"marketed","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension.","indications":["pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension)","pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension)"],"catalyst":""},{"name":"KEYTRUDA QLEX","genericName":"BERAHYALURONIDASE ALFA-PMPH","slug":"berahyaluronidase-alfa-pmph","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"WINREVAIR","genericName":"SOTATERCEPT-CSRK","slug":"sotatercept-csrk","phase":"marketed","mechanism":"Sotatercept-csrk binds to activin A and other TGF-β superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation.","indications":["Pulmonary Arterial Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}